In this episode, Director of Corporate Communications Victoria Dekker records her first PT podcast; breaking some big news with the CEO of TheraPsil, Spencer Hawkswell. Nearly two years ago, TheraPsil helped four Canadians suffering from end-of-life distress access legal psilocybin under a Section 56 exemption, but due to these exemptions expiring and the new Co-Ministers of Health (Jean-Yves Duclos and Carolyn Bennett) having other priorities, these patients and other hopeful patients have lost access to their medicine. So just this week, TheraPsil has backed a charter challenge effectively suing the Canadian government, stating that closing these exemptions violates Canadians’ Section 7 charter rights to “life, liberty and security of person,” and launched a fundraiser to help with this upcoming battle. Hawkswell discusses the creation of TheraPsil and how they help patients through this process; the current (and complicated) ways patients access psilocybin; how Canada’s Special Access Program works; how mirroring cannabis legislation is the best place to start with psilocybin; the story of Thomas Hartle, the first patient to be granted legal access to psilocybin through TheraPsil’s efforts; and TheraPsil’s just-launched Project Solace, where people who have received SAP (or Section 56) access can report back on their experience with both the medicine and the process.

The post PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada: TheraPsil’s Charter Challenge appeared first on Psychedelics Today.

Previous articleInside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines